December 8, 2017

The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study

›
Hepatobiliary Malignancies Darrick K. Li MD, PhD 1,6 , Yanjie Ren MS 2 , Daniel S. Fierer MD 3 , Stephanie Rutledge MD 1 , Obaid S. Shai...

Nonsurgical options for localized hepatocellular carcinoma

›
View  issue TOC Volume 10, Issue 4 October 2017 Pages 103–106 Review John Ha M.D. , Robert J. Wong M.D., M.S. First publi...

Where I Have Been, and I Am back.

›
Everyone, It has been a few years since I have been here to the blog. I went back to school to work on a second BS degree and finally ...
April 25, 2015

AbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX® + EXVIERA® in Chronic Hepatitis C Patients with Renal Impairment at The International Liver Congress™ 2015

›
- RUBY-I evaluates treatment-naïve, non-cirrhotic, genotype 1 chronic hepatitis C patients with severe renal impairment - In preliminary...

Merck Announces Presentation of Phase 2 Clinical Trial Results of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir at the International Liver Congress™ 2015

›
Results of C-SALVAGE Study Showed High Sustained Virologic Response Rates in Patients Who Failed Prior Combination Therapy with Certain Dire...

ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B)

›
97% of post-transplant patients with HCV genotype 1a achieved cure 91% of post-transplant patients with HCV genotype 3 achieved cure  ...

Gilead Announces Results From Studies Evaluating Sofosbuvir-Based Regimens in Chronic Hepatitis C Patients With Genotypes 2-5

›
-- High Cure Rates Observed Across a Range of Genotypes -- VIENNA, Austria--(BUSINESS WIRE)--Apr. 25, 2015-- Gilead Sciences, Inc. (Nasd...

Cancer rates among patients with hepatitis C are increased compared to those not infected

›
Public Release: 24-Apr-2015 Researchers suggest an extrahepatic manifestation of hepatitis C may be an increased risk of cancer Europe...
April 24, 2015

EMA recommends avoidance of certain hepatitis C medicines and amiodarone together

›
Press Release 24/04/2015 Concomitant use may increase risk of slow heart rate and related problems The European Medicines Agancy (EM...

Merck’s Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection

›
Data Sets Include Treatment-Naïve, Treatment-Experienced and HIV Co-Infected Patients with Chronic Hepatitis C Virus Genotypes 1, 4 or 6 Inf...

Gilead uses Georgia as free-drug testbed for hepatitis C elimination

›
Provided by Reuters Health | Wed Apr 22, 2015 11:58am EDT Gregg Alton, Gilead's executive vice president, corporate and medical af...

U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C

›
- The New Drug Application (NDA) was accepted by the U.S. Food and Drug Administration (FDA) and is based on results from the PEARL-I stud...